A multicenter observational study to develop the program for predicting therapeutic efficacy of immune checkpoint inhibitor with OXEI (OXygen saturaion Endoscopic Imaging)

A multicenter observational study to develop the program for predicting therapeutic efficacy of immune checkpoint inhibitor with OXEI (OXygen saturaion Endoscopic Imaging) - A multicenter observational study to develop the program for predicting therapeutic efficacy of immune checkpoint inhibitor with OXEI (OXygen saturaion Endoscopic Imaging)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046871

Enrollment

100

Registered

2022-02-08

Start date

2021-05-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer, gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) gastric cancer, esophageal cancer 2) Those who are 20 years old or older at the time of obtaining informed consent 3) The patient who is going to receive an immune checkpoint inhibitor 4) The patients who have the primary tumor 5) Written informed consent has been obtained from the patient. 6) Consent has been obtained for the collection of tumor tissue and blood samples for research purposes.

Exclusion criteria

Exclusion criteria: Those who are deemed inappropriate by the investigator for some reason

Design outcomes

Primary

Measure	Time frame
Correlation analysis of OXEI with clinical course and clinicopathological features	—

Countries

Japan

Contacts

Public ContactHiroki Yamashita

national cancer center hospital east Department of Gastroenterology and Endoscopy

hiryamas@east.ncc.go.jp81-4-7133-1111

Outcome results